To The Moon

As of Monday's market close, $Dow Jones(.DJI)$ edged up 0.1%, $S&P 500(.SPX)$rose about 0.4%, and $NASDAQ(.IXIC)$ gained 0.6%, showed bullish performance. Data from TradingView shows that 15 companies with a market cap of over $10 billion have reached new highs.

• Valuation pressure on tech increased: although some mega-cap names (such as Alphabet) performed well, worries about a potential “AI and tech bubble” continued to rise.

• Bond yields and policy expectations remained in focus. With uncertainty over the Federal Reserve’s next steps and the trajectory of rate cuts, some investors shifted from rate-cut optimism toward a more yield-risk-oriented view.

• External risks also persisted, including global growth concerns, trade and tech competition, and debates over the long-term returns of AI investment.

According to TradingView, on Wednesday, there were 15 stocks with market value over $10B that saw prices hit all time high. Below are the TOP 10 stocks with analyst rating of buy and ranked by market value: $Alphabet(GOOG)$ $Eli Lilly(LLY)$ $Johnson & Johnson(JNJ)$ $TJX Companies(TJX)$ $Gilead Sciences(GILD)$ $Hca Healthcare Inc(HCA)$ $Cardinal Health(CAH)$ $Insmed(INSM)$ $Natera(NTRA)$ $Loews(L)$

Looking at the specific data analysis:

• 9 companies with EPS dil growth rate over 30%: $TJX Companies(TJX)$ $CACI International Inc(CACI)$ $Hca Healthcare Inc(HCA)$ $Coca-Cola(KO)$ $Cardinal Health(CAH)$ $Alphabet(GOOG)$ $Johnson & Johnson(JNJ)$ $Eli Lilly(LLY)$ $Gilead Sciences(GILD)$

• 5 companies with negative EPS growth: $Insmed(INSM)$ $Natera(NTRA)$ $Revolution Medicines, Inc.(RVMD)$ $Old Republic(ORI)$ $Loews(L)$

• 1 company without EPS dil growth rate provided: $Lumentum(LITE)$

The following is a compilation of key drivers behind the record-high stock prices of the top 10 companies, based on publicly available information. This is for discussion purposes only.

1. $Alphabet(GOOG)$

• Core Business & Latest Business Developments: Alphabet operates through segments like Google Services, Google Cloud, and Other Bets. It continues to lead in AI with initiatives like AI Max and Gemini, which are driving growth in search ads and cloud services. Recent product launches include AI Overviews and AI Mode, enhancing user experience and increasing query volume.

• Recent Financial Highlights: In Q2 2025, Alphabet reported consolidated revenues of $96.4 billion, up 14% year-over-year. Google Services revenues increased 12% to $82.5 billion, while Google Cloud revenues grew 32% to $13.6 billion. Net income increased 19%, and EPS increased 22% to $2.31. The company plans to increase its 2025 capital expenditures to approximately $85 billion, reflecting its commitment to technical infrastructure expansion. Alphabet also spent $11.5 billion on share buybacks and $2.5 billion on dividends during the quarter.

  

2. $Eli Lilly(LLY)$

• Core Business & Latest Business Developments: Eli Lilly is a global pharmaceutical company focused on developing innovative medicines in areas such as diabetes, obesity, oncology, and immunology. Its key products include Mounjaro and Zepbound, which have seen significant growth. The company continues to invest in research and development to expand its pipeline of new drugs.

• Recent Financial Highlights: In Q3 2025, Eli Lilly reported revenue of $17.60 billion, a 54% increase year-over-year. Net income was $5.58 billion, or $6.21 per share. Mounjaro generated $6.52 billion in revenue, up 109% from the same period last year, while Zepbound contributed $3.59 billion, up 184% year-over-year. The company raised its full-year revenue guidance to between $63 billion and $63.5 billion and adjusted profit guidance to between $23 and $23.70 per share.

  

3. $Johnson & Johnson(JNJ)$

• Core Business & Latest Business Developments: Johnson & Johnson is a diversified healthcare company with operations in pharmaceuticals, medical devices, and consumer health. The company continues to focus on innovation and expanding its product portfolio in these segments, including recent advancements in pharmaceuticals and medical devices.

• Recent Financial Highlights: In Q2 2025, Johnson & Johnson reported strong financial results. The company's revenue grew by 12% year-over-year, driven by robust performance across all segments. Pharmaceuticals revenue increased by 15%, medical devices revenue grew by 10%, and consumer health revenue rose by 5%. The company's net income was $4.5 billion, with earnings per share of $1.62. Johnson & Johnson also maintained a strong dividend payout, reflecting its commitment to shareholder returns.

  

4. $TJX Companies(TJX)$

• Core Business & Latest Business Developments: TJX Companies operates as a global retailer of discounted fashion apparel and home goods. The company continues to expand its global presence and enhance its omnichannel retail strategy. Recent highlights include the opening of 13 new stores in the second quarter of FY2026, bringing the total store count to 5,134.

• Recent Financial Highlights: In Q2 2026, TJX reported net sales of $13.5 billion, up 7% year-over-year. Earnings per share were $1.12, exceeding expectations. The company's gross profit margin was 32.3%, up 170 basis points year-over-year. Net cash from operating activities was $4.4 billion, with free cash flow of $2.0 billion.

  

5. $Gilead Sciences(GILD)$

• Core Business & Latest Business Developments: Gilead Sciences is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutics across multiple disease areas, including virology, inflammation, and oncology. Recent highlights include the recent FDA approval of its drug combination Troprosta/Remsima for the treatment of sickle cell disease in adolescents and adults. The company continues to expand its pipeline and invest in research and development to address unmet medical needs.

• Recent Financial Highlights: In Q3 2025, Gilead Sciences reported total revenues of $7.8 billion, marking a 3% increase year-over-year. The company's net income was $2.08 billion, or $2.43 per share. Adjusted EBITDA for the quarter stood at $3.9 billion. The company remains committed to driving growth and innovation across its therapeutic areas.

  

6. $Hca Healthcare Inc(HCA)$

• Core Business & Latest Business Developments: HCA Healthcare (HCA) operates one of the largest networks of hospitals and outpatient care facilities in the United States, providing acute care, surgical services, emergency care, and specialized clinical services. The company emphasizes expansion of inpatient and outpatient capacity, increased surgical volumes, and integrated care delivery across its hospitals, surgery centers, and urgent-care sites.

• Recent Financial Highlights: HCA reported strong momentum in its latest results, with Q3 2025 revenue increasing about 9.6% to over $19 billion, driven by higher surgical procedures and outpatient activity. Net income rose approximately 29%, resulting in a ~43% increase in diluted EPS, while adjusted EBITDA grew around 18%, reflecting improved operational leverage and cost management.

  

7. $Cardinal Health(CAH)$

• Core Business & Latest Business Developments: Cardinal Health (CAH) is a global healthcare distributor providing pharmaceuticals, medical supplies, and specialty solutions to hospitals, pharmacies, and care providers. Its business centers on large-scale drug distribution, medical products, and growing home-care and specialty pharmacy services.

  Recent Financial Highlights: In Q1 FY26, the company posted strong results with revenue up 22%, non-GAAP operating earnings up 37%, and non-GAAP EPS up 36%, driven by specialty pharmaceutical demand and expanding home-care solutions. Cardinal Health also raised its full-year FY26 earnings and cash-flow outlook.

  

8. $Insmed(INSM)$

• Core Business & Latest Business Developments: Insmed is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases, particularly in respiratory and pulmonary disorders. Its commercial product portfolio includes ARIKAYCE (for refractory Mycobacterium avium complex lung disease) and BRINSUPRI (brensocatib) for non-cystic-fibrosis bronchiectasis, and it is advancing a pipeline of therapies (such as TPIP) for pulmonary hypertension and other rare conditions.

• Recent Financial Highlights: In Q3 2025 (ended September 30) Insmed reported total product revenues of approximately US $142.3 million, a ~52% increase year-over-year. The company remains unprofitable, recording a net loss of US $370.0 million, or US $1.75 per share, compared with a loss of US $220.5 million (US $1.27 per share) in the same quarter a year ago. PR Newswire It also held roughly US $1.7 billion in cash, cash equivalents and marketable securities as of September 30 2025.

  

9. $Natera(NTRA)$

• Core Business & Latest Business Developments: Natera, Inc. (ticker: NTRA) is a molecular diagnostics company that develops and commercializes cell-free DNA (cfDNA) tests across three main domains: women’s health (non-invasive prenatal testing such as Panorama™), oncology (personalized tumor assays such as Signatera™ for minimal residual disease), and organ health (e.g., Prospera™ for transplant rejection monitoring).

• Recent Financial Highlights: In Q3 2025 (ended Sept 30 2025), Natera reported total revenues of approximately US $592.2 million, a year-over-year increase of ~34.7%. Gross margin rose to ~64.9% (vs ~61.8% a year ago). Testing volumes increased ~15.2% to ~893,600 tests, with a ~53.9% jump in oncology (MRD) tests (~211,000 units). natera.com+1 However, the company posted a net loss of ~US $87.5 million (-$0.64 per diluted share) vs a loss of US $31.6 million (-$0.26 per share) in Q3 2024. Natera also raised its full-year 2025 revenue guidance to US $2.18 billion – US $2.26 billion, up from its prior range.

  

10. $Loews(L)$

• Core Business & Latest Business Developments: Loews Corporation is a diversified holding company with operations across insurance (via its majority stake in CNA Financial Corporation), energy midstream (via Boardwalk Pipelines, which handles transportation and storage of natural gas and NGLs), hospitality (via Loews Hotels & Co), and packaging (via Altium Packaging).

• Recent Financial Highlights: In the third quarter of 2025, Loews reported net income of US$504 million, or US$2.43 per share, up from US$401 million (US$1.82 per share) in Q3 2024. Key drivers included a 43% year-over-year increase in income from CNA (thanks to improved underwriting results and lower catastrophe losses), and a 22% net income improvement at Boardwalk Pipelines (driven by growth projects and higher re-contracting rates).

  

Conclusion

The record-high stock prices of these ten companies on November 20th, 2025. Across the healthcare, technology, retail, and diagnostics sectors, overall macro performance in the latest quarter reflected broad-based strength driven by AI adoption, breakthrough pharmaceuticals, resilient consumer demand, and expanding healthcare services. Tech leaders like Alphabet continued to scale AI infrastructure and cloud growth, while major pharmaceutical companies such as Eli Lilly, Johnson & Johnson, and Gilead delivered strong revenue gains supported by blockbuster drugs and innovation pipelines. Healthcare services and distribution—HCA and Cardinal Health—benefited from rising procedure volumes and specialty-drug demand. Consumer-facing businesses like TJX showed steady demand despite macro uncertainty, and advanced diagnostics and biotech firms such as Natera and Insmed saw rapid growth in cutting-edge testing and rare-disease therapies.

Call to Action

We invite you to explore these companies further and consider their potential impact on your investment portfolio or business strategy.

Join the conversation and share your insights on these market leaders. What do you think will be the next big trend driving their growth? Let us know in the comments below.

For SG users only, A tool to boost your purchasing power and trading ideas with CashBoost!

For whom haven't open CBA can know more from below:

🏦 Open a CBA today and enjoy privileges of up to SGD 20,000 in trading limit with 0 commission. Trade SG, HK, US stocks as well as ETFs unlimitedly!

Complete your first Cash Boost Account trade with a trade amount of ≥ SGD 5000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.

Click to access the activity

Other helpful links:

• 💰Join the TB Contra Telegram Group to Get $10 Trading Vouchers Now🎉

• How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.